Comorbidity indices in orthopaedic surgery: a narrative review focused on hip and knee arthroplasty

SaTia T. Sinclair1
Ahmed K. Emara1
Melissa N. Orr1
Kara M. McConaghy2
Alison K. Klika1
Nicolas S. Piuzzi1

Comorbidity indices currently used to estimate negative postoperative outcomes in orthopaedic surgery were originally developed among non-orthopaedic patient populations.

While current indices were initially intended to predict short-term mortality, they have since been used for other purposes as well.

As the rate of hip and knee arthroplasty steadily rises, understanding the magnitude of the effect of comorbid disease on postoperative outcomes has become increasingly more important.

Currently, the ASA classification is the most commonly used comorbidity measure and is systematically recorded by the majority of national arthroplasty registries.

Consideration should be given to developing an updated, standardized approach for comorbidity assessment and reporting in orthopaedic surgery, especially within the setting of elective hip and knee arthroplasty.

Keywords: comorbidity; hip arthroplasty; knee arthroplasty

Cite this article: EORT Open Rev 2021;6:629-640.
DOI: 10.1302/2058-5241.6.200124

Introduction

Total joint arthroplasty is a common surgical procedure worldwide, with more than 1 million total hip arthroplasties (THAs) performed globally each year and several countries reporting nearly 100,000 annual total knee arthroplasties (TKAs).1,2 By 2030, it is projected that the annual procedure volume for primary THA and TKA in the United States alone will grow by 71% and 85% respectively, totalling an estimated 635,000 primary THAs and nearly 1.26 million primary TKAs.3 Additional reports within the field of lower limb arthroplasty agree with this continued growth in procedure volume around the world.1,4-6 While the majority of patients experience improved postoperative pain and function without adverse events, there remains a risk of complications, particularly for patients with multiple comorbidities. Comorbidity is generally defined as the presence of more than one distinct disease or medical condition in a single individual.7 Diagnoses such as diabetes,8 respiratory disease,8 chronic kidney disease,9 and depression10 have all been associated with adverse clinical outcomes, including infection,8 extended hospital stay,9 and mortality,10 after arthroplasty. This information is vital to orthopaedic surgeons when determining best practices for patient management, as it impacts the long-term health of the patient. Estimating the magnitude of the effect these diagnoses have on outcomes can significantly aid clinical decision-making, yet there is no uniform comorbidity reporting method within the area of hip and knee reconstruction to standardize their assessment. The utility of such comorbidity assessments may aid in appropriate risk stratification of patients not only for preoperative optimization but for reimbursement purposes.

Currently, comorbidity measurement in orthopaedics relies on indices originally intended for patient populations in other specialties. Two of the most commonly used comorbidity indices include the Charlson Comorbidity Index (CCI)11 and the Elixhauser Comorbidity Measure (ECM).12 Charlson et al11 developed the CCI for estimating risk of mortality in non-surgical patients. 11 The Elixhauser Comorbidity Measure was created for use with administrative data to estimate adverse outcomes in the setting of acute care.12 These comorbidity indices provide a systematic method to predict the risk of various outcomes in the presence of comorbid disease and have also been used to control for confounding in multiple studies.13,14 Though originally intended to predict mortality, these tools have been helpful in elucidating outcomes for patients with
varying degrees of comorbidity. Further validation is also needed for both specific patient populations and specific outcomes (e.g., readmission, reoperation). However, no standardized system of comorbidity reporting currently exists in orthopaedic surgery, specifically for patients undergoing hip and knee arthroplasty.

Therefore, the purpose of this study was to review the comorbidity indices currently used in arthroplasty research to better understand their properties and potentially highlight the need for a consistent, data-driven approach for standardized comorbidity assessment and reporting in arthroplasty-related research. Specifically, we assessed the development and validation of: (1) the American Society of Anesthesiologists Physical Status (ASA-PS) Classification; (2) the Charlson Comorbidity Index; (3) the Age-adjusted Charlson Comorbidity Index; (4) the Modified Charlson Comorbidity Index; (5) the Elixhauser Comorbidity Measure; (6) the Weighted Elixhauser Comorbidity Measure; (7) the modified Frailty Index; (8) the 5-Factor modified Frailty Index; and (9) the RxRisk-V (Table 1).

American Society of Anesthesiologists Physical Status Classification

In 1941, members of the American Society of Anesthesiologists developed the ASA Physical Status Classification for the assessment of a patient’s preoperative condition.15–18 This classification system contained seven categories which described overall health status, ranging from no systemic disturbance (Class 1) to moribund (Class 7). Though it allowed statistics regarding preoperative health, type of operation, and outcome to be recorded, it was not intended to provide a prediction of postoperative outcomes.15,18 Upon its development, Dripps et al19 revised the classification system, giving rise to the current model comprising six classes and a separate designation for emergency procedures (Table 2).17,19 Currently, the ASA classification is the most commonly used comorbidity measure and is systematically recorded by the majority of national and regional arthroplasty registries, including the National Joint Registry in England, Wales, Northern Ireland, the Isle of Man, and the States of Guernsey, as well as the Swedish, Finnish, and Norwegian Arthroplasty Registers, and several others.20 As arthroplasty registries constitute a major source for hip and knee arthroplasty outcomes, the widespread use of the ASA class is undeniable.

In the setting of arthroplasty, ASA-PS class has been widely utilized. Joshi et al21 examined the relationship between ASA-PS class and length of stay (LOS). Among a cohort of 245 patients who underwent THA and TKA, the ASA-PS class had a positive correlation with postoperative LOS (p < 0.01).21

---

### Table 1. Summary of comorbidity indices used in orthopaedic surgery

| Comorbidity measure | American Society of Anesthesiologists Physical Status Classification | Charlson Comorbidity Index (CCI) | Age-Adjusted Charlson (ACCI) | Modified Charlson (mCCI)** | Elixhauser Comorbidity Measure (ECM) | Weighted Elixhauser | Modified Frailty Index (mFI) | 5-Factor modified Frailty (mFI-S) | RxRisk-V |
|---------------------|---------------------------------------------------------------------|---------------------------------|----------------------------|---------------------------|------------------------------------|--------------------|--------------------------|-----------------------------|-----------|
| Year of publication | 1941                                                                | 1987                            | 1994                       | 2017                      | 1998                               | 2009               | 2013                     | 2018                        | 2003      |
| Author(s)           | Sáslad et al15                                                      | Charlson et al11                 | 218 patients admitted to   | 6,121                      | Elixhauser et al12                 | van Waijenroet et al15 | Velanovich et al41       | Subramaniam et al41         | Sloan et al43        |
| Original study      | Decision by members of the American Society of Anesthesiologists to classify a patient based solely on physical status. | 604 patients admitted to the internal medicine service at New York Hospital-Cornell Medical Center in 1984. | 218 patients who underwent elective general surgery between 1982 and 1985. | 6,121 revision hip arthroplasty patients between 2006 and 2013. | 1,779,167 patients admitted to an acute care hospital in 1992. | 228,565 adult hospitalizations at The Ottawa Hospital, Canada between 1996 and 2007. | 971,414 surgical inpatients across all surgical specialties between 2005 and 2009. | 90-day morbidity, mortality, readmission, infection | 90-day readmission, 30-day mortality, postoperative complications, reoperation, readmission, and surgical site infection |
| Type of data        | Clinical                                                            | Clinical                        | ACS NSQIP Clinical data    | Administrative             | Length of stay, postoperative complications, discharge disposition, and EQ-SD index | 30-day morbidity, mortality, readmission, and surgical site infection | 30-day mortality, postoperative complications, reoperation, readmission, and surgical site infection | 90-day readmission, 30-day mortality, postoperative complications, reoperation, readmission, and surgical site infection | 90-day readmission, 30-day mortality, postoperative complications, reoperation, readmission, and surgical site infection |
| Predicted outcome(s) in arthroplasty | 3-month revision/ reoperation, 6-month mortality, 6-month Oxford Scores, 2-year revision, length of stay, health-related quality of life, any adverse event | Hospital readmission, length of stay, EQ visual analogue scale | 5-year mortality | Mortality, major and minor complications, length of stay, blood transfusion, and any adverse event | 90-day readmission | 30-day morbidity, mortality, readmission, and surgical site infection | 90-day readmission | 30-day morbidity, mortality, readmission, and surgical site infection | 90-day readmission, 30-day mortality, postoperative complications, reoperation, readmission, and surgical site infection |
| Number of variables | N/A                                                                | 19                              | 19                         | 10                        | 30                    | 21                   | 11                        | 5                           | 45                     |
| Single summary score | No                                                                 | Yes                             | Yes                        | Yes                       | No                    | Yes                  | Yes                       | Yes                          | No                     |

Notes: ACS NSQIP, American College of Surgeons National Surgical Quality Improvement Program; ASA, American Society of Anesthesiologists; EQ, European Quality of Life; EQ-SD, European Quality of Life Five Dimensions; VHA, Veterans Health Administration.

**Reflects information for the mCCI used in orthopaedics by Lakomkin et al.44
Additional work by Hooper et al\textsuperscript{22} investigated the relationship between the ASA class and six-month mortality, six-month Oxford Hip and Knee Scores, and two-year revision among 22,600 THA patients and 18,434 TKA patients.\textsuperscript{22} Among the THA cohort, Hooper and colleagues reported a statistically significant difference in the six-month mortality rate between patients with an ASA class of 1 (0.12\%, 95\% confidence interval [CI]: 0.03–0.30, \(p < 0.001\)) and patients with an ASA class of 4 (10.06\%, 5.96–15.62, \(p < 0.001\)).\textsuperscript{22} Higher ASA class was also associated with lower Oxford Hip Scores (ASA Class 1: 42.1±0.3, 95\% CI: 41.6–42.6; ASA class 4: 35.2±2.1, 95\% CI: 31.1–39.2, \(p = 0.005\)), indicating worse outcome with higher comorbidity burden.\textsuperscript{22} Investigators also noted statistically significant differences in the two-year revision rate between ASA classes 1 and 3 only when controlling for age and sex (hazard ratio[H R] = 1.39, 95\% CI: 1.04–1.95, \(p = 0.015\)).\textsuperscript{22} While there were no differences between ASA classes with respect to early revision among the TKA cohort, higher ASA class was associated with increased six-month mortality rate (ASA Class 1: 0.12\%, 95\% CI: 0.01–0.43; ASA Class 4: 2.44\%, 95\% CI: 0.30–8.53, \(p < 0.05\)).\textsuperscript{22}

Ferguson et al\textsuperscript{23} evaluated the relationship between ASA class and three-month revision and reoperation among patients found in the Geneva and Swedish Hip Arthroplasty Registers. In this study, investigators reported that higher ASA score had a statistically significant association with increased risk of both revision (ASA Class 3 and 4: HR = 3.3, 95\% CI: 2.6–4.0, \(p < 0.001\)) and reoperation (ASA class 3 and 4: HR = 3.2, 95\% CI: 2.3–4.3, \(p = 0.001\)).\textsuperscript{23} Further investigation by Teni et al\textsuperscript{24} examined the relationship between ASA class and postoperative health-related quality of life among patients who underwent THA and were registered in the Swedish Hip Arthroplasty Register. Teni and colleagues reported that ASA class was predictive of health-related quality of life after adjusting for demographic, clinical, and patient-reported outcomes, as a decline in quality of life was consistently observed with increasing ASA class.\textsuperscript{24}

Ondeck et al\textsuperscript{14} assessed the discriminative ability of the ASA-PS classification when predicting any adverse event following THA. The system was tested in a cohort of 64,792 patients and had an area under the curve (AUC) of 0.584 (95\% CI: 0.578–0.589), where AUC is equivalent to the concordance probability (c-statistic).\textsuperscript{14} Additional investigation by Silman et al\textsuperscript{25} evaluated the relationship between the ASA-PS class and one-year mortality among 418,916 primary THAs identified within all international arthroplasty registries containing ASA-PS class and mortality data. Investigators reported that increased ASA-PS score was associated with a statistically significant increase in risk of mortality within one year following THA (ASA class 1: 0.18\%, 95\% CI: 0.12–0.25 vs. ASA class 4: 8.9\%, 95\% CI: 6.7–12).\textsuperscript{25} Silman and colleagues also noted variation in the distribution of ASA class between registries.\textsuperscript{25}

Although the ASA-PS classification has been commonly used within the arthroplasty literature, the method of classifying patients in this system remains relatively unspecific and subjective, leading to variability across studies.\textsuperscript{17} Similar to the Charnley classification, which divides patients into three categories based on severity of conditions that affect mobility (e.g. A: single joint arthropathy and no comorbidity; B: two joints in need of arthroplasty; C: multiple joints in need of arthroplasty or severe medical impairment),\textsuperscript{26} this system relies on clinical perception of the significance of disease. Recognizing that severity of diagnosis may not always be assessed retrospectively, such risk models are not ideal for research which collect data via medical chart review.\textsuperscript{26} However, since 2015, more recent studies have included scoring examples alongside the ASA score, thereby decreasing interobserver variability among both anaesthesiologists and non-anaesthesiologist physicians and allowing for improved grade assignment.\textsuperscript{27,28}

\begin{table}
\centering
\begin{tabular}{ll}
\hline
Revised ASA Physical Status Classification (Dripps et al)\textsuperscript{19} & \\
\hline
PS Class 1: & no systemic condition \\
PS Class 2: & moderate systemic condition (pre-existent or caused by the condition being treated by the operation) \\
PS Class 3: & severe systemic condition \\
PS Class 4: & extreme systemic disorders, eminent threat to life regardless of the type of treatment \\
PS Class 5: & class 1 or 2 patients undergoing an emergency operation \\
PS Class 6: & class 3 or 4 patients undergoing an emergency operation \\
PS Class 7: & moribund, not expected to survive 24 hours with or without the operation \\
\hline
ASA I: & normal, healthy patient \\
ASA II: & mild systemic condition \\
ASA III: & severe systemic condition \\
ASA IV: & severe systemic condition that is a constant threat to life \\
ASA V: & moribund, not expected to survive without the operation \\
ASA VI: & declared brain-dead, organs are being removed for donor purposes \\
\hline
\end{tabular}
\caption{The American Society of Anesthesiologists Physical Status Classification}
\end{table}

Notes. ASA, American Society of Anesthesiologists; PS, physical status.
\*E: may be added to indicate an emergency operation.

Source: Adapted from Fitz-Henry.\textsuperscript{15–17,19}
Charlson Comorbidity Index

The Charlson Comorbidity Index (CCI) was originally developed by Charlson et al.\textsuperscript{11} in 1987 with the intention of creating a system of classification for comorbid diseases that may affect the short-term risk of mortality for patients in prospective studies.\textsuperscript{11} The initial cohort for this index was composed of 604 patients admitted to the internal medicine service during a one-month period at New York Hospital-Cornell Medical Center in 1984. For each patient, comorbidities were recorded and assigned a weight at the time of admission.\textsuperscript{11,29} The weight of each comorbid condition was then added to provide a total comorbidity score ranging from 0 to 37, with a higher score indicating a larger quantity or worse severity of disease.\textsuperscript{11,30} Overall, the original CCI identified 19 comorbidities that demonstrated an effect on in-hospital and one-year mortality (Table 3).\textsuperscript{11} Subsequent studies have often combined any tumour, leukaemia, and lymphoma into a single category of any malignancy, yielding a total of 17 comorbid conditions.\textsuperscript{30–32}

Following its development, the Charlson Index was adapted to include International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes.\textsuperscript{30,31} A study conducted by Deyo et al.\textsuperscript{11} identified ICD-9-CM codes which corresponded to the comorbid conditions of any malignancy, yielding a total of 17 comorbidities.\textsuperscript{30–32}

Additional work conducted by Quan et al.\textsuperscript{35} in 2011 sought to update the original Charlson Index based on data among a cohort of 55,929 patients up to one year following hospital admission. In this study, five of the 17 Charlson comorbidities no longer had an association with mortality during this timeframe.\textsuperscript{35} Therefore, they evaluated an adapted Charlson Index model which included only 12 comorbid conditions.\textsuperscript{35} Quan and colleagues reported that the adapted index demonstrated similar discrimination to the original CCI for in-hospital mortality, 30-day mortality, and one-year mortality (Quan-adapted CCI: c-statistic = 0.882, 0.884, 0.897, respectively; original CCI: c-statistic = 0.884, 0.886, 0.899, respectively).\textsuperscript{35}

Further work conducted by Brusselaers and Lagergren\textsuperscript{36} explored additional ICD-adaptations of the CCI, and highlighted the utility of the Royal College of Surgeons (RCS) Charlson Score. This version of the score removed peptic ulcer disease and grouped similar diseases regardless of severity, ultimately encompassing 14 categories.\textsuperscript{36} The method of weighting in the original Charlson Index has been a point of controversy, with some investigators believing the addition of risk ratios performed by Charlson and colleagues was erroneous.\textsuperscript{37,38} The RCS adaptation of the index eliminated the use of weights within the scoring system and instead counted the number of diagnoses (e.g. 0, 1, 2, or ≥ 3).\textsuperscript{36} Authors noted that while the RCS Charlson Score is appropriate for use in registry-based research and relatively easy to use, it may underestimate the effect of malignancy, AIDS, and moderate liver disease. This deficiency would make it less effective when evaluating the impact of comorbid disease among certain patient populations.\textsuperscript{36}

Since its development, several studies have elaborated on the utility of the Charlson Index within orthopaedics. Voskuil et al.\textsuperscript{39} analysed the efficacy of the CCI as a predictive tool for readmission, adverse events, transfusion risk, and mortality in a sample of 30,126 orthopaedic surgeries performed between 2008 and 2011. In the arthroplasty cohort, every point increase in CCI score added an additional 0.45% (95% CI: 0.0023–0.0066, p < 0.001) and 0.11% (95% CI: 0.000027–0.0022, p < 0.044) risk for readmission and transfusion, respectively.\textsuperscript{39} The index did not predict postoperative adverse events or mortality after arthroplasty; however, CCI score was positively associated

| Table 3. Variables of the original and modified Charlson Comorbidity Indices |
|---------------------------------|---------------------------------|
| **Charlson Comorbidity Index (CCI)** | **Modified CCI (mCCI)** |
| Conditions with assigned weight of 1 | Conditions with assigned weight of 1 |
| Cerebrovascular disease | Chronic obstructive pulmonary disease |
| Chronic pulmonary disease | Congestive heart failure |
| Congestive heart failure | Diabetes mellitus |
| Connective tissue disease | Peripheral vascular disease or pain at rest |
| Dementia | Myocardial infarction |
| Diabetes mellitus | Transient ischemic attack or stroke |
| Mild liver disease | Congestive heart failure |
| Myocardial infarct | Ulcer disease |
| Peripheral vascular disease | Conditions with assigned weight of 2 |
| Ulcer disease | Hemiplegia |
| Any tumour | Renal failure |
| Diabetes with end organ damage | Metastatic solid tumour |
| Hemiplegia | AIDS |
| Leukaemia | Metastatic solid tumour |
| Lymphoma | Moderate or severe renal disease |
| Moderate or severe renal disease | Conditions with assigned weight of 3 |
| Conditions with assigned weight of 3 | Acute or oesophageal varices (indicate liver disease) |
| Moderate or severe liver disease | Conditions with assigned weight of 6 |
| Conditions with assigned weight of 6 | Disseminated cancer |

*Notes. AIDS, Acquired Immunodeficiency Syndrome.
**The original CCI by Charlson et al.\textsuperscript{11}
***The mCCI used in orthopaedics by Lakomkin et al.\textsuperscript{44}
with mortality following shoulder, trauma, and oncologic surgeries. These findings indicated that the utility of the index may vary across orthopaedic subspecialties and procedures.

Melfi et al. tested the validity of the adapted CCI in patients who underwent TKA between 1985 and 1989. This study analysed the ability of the index to predict hospital LOS among a total of 249,744 patients and 30-day mortality among 238,999 patients. When estimating LOS, the adapted index had a coefficient of determination \( (R^2) \) of 0.175 in comparison to the baseline model of no index \( (R^2 = 0.174) \), indicating that CCI was not useful in predicting LOS after knee arthroplasty. Regarding the ability to predict 30-day mortality, the index had a c-statistic of 0.653 which was only a slight improvement from the baseline model of no index \( (c\text{-statistic} = 0.645) \). Greene and colleagues cited the index’s original purpose to explain the CCI’s negligible influence on PROMs.41

Additional work conducted by Greene et al. investigated the influence of the Charlson Index on patient-reported outcome measures (PROMs) in the setting of THA. In this study, investigators evaluated the impact of the CCI on the EQ-SD index, EQ visual analogue scale (VAS), pain VAS, and satisfaction VAS among a cohort of 22,263 patients in the Swedish National Patient Register who underwent THA between 2002 and 2007. Greene and colleagues reported the CCI had minimal impact on the postoperative EQ-SD index \((\beta = -0.023, 95\% \text{ CI: } -0.035 \text{ to } -0.011, p < 0.001)\) and the postoperative EQ VAS \((\beta = -3.407, 95\% \text{ CI: } -4.400 \text{ to } -2.414, p < 0.001)\) regardless of timeframe. Investigators noted the CCI did not influence the pain VAS or the satisfaction VAS. Greene and colleagues cited the index’s original purpose of predicting mortality and hospitalization as a plausible explanation for the CCI’s negligible influence on PROMs.41

**Age-adjusted Charlson Comorbidity Index**

Following the initial study, Charlson et al. validated a model that incorporated age and comorbidity into a single prognostic variable. This risk model used the original CCI and added one point to the overall comorbidity score for every decade of age over 40 years.11,42 The age-adjusted CCI (ACCI) was tested within a cohort of 218 patients who underwent elective general surgery between July 1982 and September 1985. Using the proportional hazards model, this study showed the combined age-comorbidity index was highly predictive of mortality within five years (each age-comorbidity unit: relative risk = 1.45, 95% CI: 1.25–1.68, \( p < 0.0001 \)).42

Within orthopaedic studies, the ACCI has been evaluated for its ability to predict five-year mortality following hip fracture surgery. Jiang et al. assessed the age-adjusted CCI among 1,057 patients aged 60 years and older who received surgical treatment between January 2007 and December 2009. A multiple regression model including ACCI, age, gender, and fracture pattern demonstrated satisfactory predictive ability \( (c\text{-statistic} = 0.68) \), where a c-statistic of 1, 0.70, and 0.50 indicated predictive ability that was perfect, good, and no better than chance, respectively. The five-year survival was 89.3%, 62.1%, and 41.8% for patients with an age-comorbidity score of \( \leq 3 \), \( 4 \) to 5, and \( \geq 6 \), respectively. The odds ratio for an ACCI score of 4 or 5 was 6.23 (95% CI: 3.12–14.46, \( p < 0.001 \)), while the odds ratio for an ACCI score \( \geq 6 \) was 13.57 (95% CI: 6.72–31.84, \( p < 0.001 \)), indicating a higher age-comorbidity score was associated with a statistically significant increase in risk of mortality. According to these findings, the age-adjusted Charlson Index shows promise of satisfactory predictive ability for five-year survival after hip fracture surgery, yet additional information regarding the predictive power of this index for other outcomes is limited.

**Modified Charlson Comorbidity Index**

Additional studies have given rise to what is now known as the modified Charlson Comorbidity index (mCCI).14,44–46 Lakomkin et al. used a modified CCI with comorbidities found in the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database among a cohort of 6,121 patients who underwent revision hip arthroplasty between 2006 and 2013 (Table 3). Similar to the age-adjusted Charlson, one point was added to the overall comorbidity score for every decade of age over 40 years. Using this mCCI, higher index scores were associated with increased mortality \( (OR = 1.89, 95\% \text{ CI: } 1.64–2.18, p < 0.001) \), major \( (OR = 1.12, 95\% \text{ CI: } 1.05–1.20, p = 0.001) \) and minor \( (OR = 1.53, 95\% \text{ CI: } 1.39–1.69, p < 0.001) \) complications, increased LOS \( (OR = 1.32, 95\% \text{ CI: } 1.26–1.39, p < 0.001) \), and blood transfusions \( (OR = 1.14, 95\% \text{ CI: } 1.09–1.20, p < 0.001) \).

Assessing the predictive power of the modified Charlson Index, Ondeck et al. investigated the performance of the index among 64,792 THA patients identified using NSQIP data. An analysis of the discriminative ability of the index for any adverse event showed the mCCI had an AUC of 0.534 (95% CI: 0.529–0.539), performing more poorly than both the ASA (AUC 0.584, 95% CI: 0.578–0.589) and the modified Frailty Index (mFI) (AUC 0.567, 95% CI: 0.561–0.573).44

Although it has become more commonly used within the literature, these findings suggest that the mCCI has
Table 4. Variables of the Elixhauser Comorbidity Measure (ECM), ACS NSQIP Surgical Risk Calculator, and modified Frailty Index (mFI)

| Elixhauser Comorbidity Measure | Diabetes (uncomplicated) | Coagulopathy |
|--------------------------------|---------------------------|--------------|
| *Cardiac arrhythmias           | Diabetes (complicated)    | Obesity      |
| Valvular disease               | Renal failure             | Weight loss  |
| Pulmonary circulation disorders | Liver disease             | Fluid/electrolyte disorders |
| Peripheral vascular disorders  | Peptic ulcer disease (excluding bleeding) | Blood loss anaemia |
| Hypertension (combined)        | AIDS/HIV infection        | Deficiency anaemia |
| Hypertension – uncomplicated   | Lymphoma                  | Alcohol abuse |
| Hypertension – complicated     | Metastatic cancer         | Drug abuse |
| Paralysis                      | Solid tumour without metastasis | Psychoses |
| Other neurologic disorders     | Rheumatoid arthritis/collagen vascular diseases | Depression |
| Chronic pulmonary disease      |                           |              |

ACS NSQIP Surgical Risk Calculator

| Age group                     | System sepsis (48 hours preop.) | Dyspnea |
|--------------------------------|---------------------------------|---------|
| Sex                           | Ventilator dependent            | Current smoker within 1 year |
| Functional status             | Disseminated cancer             | History of COPD |
| Emergency case                | Diabetes                        | Dialysis |
| ASA Class                     | Hypertension requiring medication | Acute renal failure |
| Steroid use for chronic condition | Previous cardiac event             | BMI class |
| Ascites (30 days preop.)      | Congestive heart failure (30 days preop.) | CPT-specific linear risk |

Modified Frailty Index

| *Diabetes mellitus            | Cerebrovascular problems       |
| *Congestive heart disease     | History of stroke              |
| Hypertension requiring medication | Clounding or delirium        |
| Myocardial infarction         | Respiratory problems, * COPD  |
| Cardiac problems              | * Decreased peripheral pulses  |
|                               | * Functional status            |

Notes. AIDS, Acquired Immunodeficiency Syndrome; ACS NSQIP, American College of Surgeons National Quality Improvement Program; ASA, American Society of Anesthesiologists; COPD, chronic obstructive pulmonary disease; BMI, body mass index; CPT, Current Procedural Terminology; HIV, Human Immunodeficiency Virus.

* Included in the S-Factor modified Frailty Index (mFI-5).
* Included in the original ECM but removed in subsequent versions.
using ICD-10-CM codes had a c-statistic of 0.870.32 Both models demonstrated improved predictive ability in comparison to the original ECM (c-statistic = 0.868).32 A study conducted by Fortin et al48 validated the Elixhauser model with enhanced ICD-9-CM coding among 3,273,298 patients within the Cerner Health Facts® US Database who received care between 2002 and 2011. In this study, the model showed strong discrimination when predicting in-hospital and one-year mortality (c-statistic = 0.887, 95% CI: 0.885–0.889, p < 0.0001, and c-statistic = 0.884, 95% CI: 0.883–0.886, p < 0.0001, respectively).48 Databases sponsored by the Agency for Healthcare Research and Quality (AHRQ), such as the National and State Inpatient Sample databases within the Healthcare Cost and Utilization Project (HCUP), have afforded the feasibility of extended research utilizing administrative data. The specific ICD codes used for the calculation of the ECM, CCI, and other classification tools are provided within the coder R package.49

In orthopaedic studies, the Elixhauser measure has demonstrated better discriminative ability for postoperative complications, LOS, and discharge to a facility.50 Ondeck et al50 evaluated the predictive ability of the ECM among 68,680 THA patients identified in the 2013 National Inpatient Sample. The ECM had an AUC of 0.739 (95% CI: 0.728–0.750) and 0.647 (95% CI: 0.643–0.652) when estimating LOS and discharge to a facility, respectively.50 This performance was better than that of both the CCI (AUC 0.642, 95% CI: 0.631–0.655 and AUC 0.589, 95% CI: 0.585–0.594, respectively) and the modified Frailty Index (AUC 0.618, 95% CI: 0.607–0.630 and AUC 0.605, 95% CI: 0.600–0.609, respectively).50 The ECM also showed increased discrimination relative to the CCI and mFI with respect to the occurrence of the Centers for Medicare & Medicaid Services procedure-specific complication measures for elective primary THA and TKA.50

In an aforementioned study conducted by Greene et al,41 investigators examined the influence of the Elixhauser measure on PROMs among a cohort of 22,263 patients in the setting of THA. Here, Greene and colleagues observed minimal impact of the Elixhauser measure on the postoperative EQ-SD index (β = −0.010, 95% CI: −0.015 to −0.004, p < 0.001) and the postoperative EQ VAS (β = −0.886, 95% CI: −1.353 to −0.420, p < 0.001).41 Unlike the CCI, the Elixhauser measure had a small influence on the pain VAS (β = 0.522, 95% CI: 0.091–0.954, p = 0.018) and the satisfaction VAS (β = 0.628, 95% CI: 0.141–1.116, p = 0.012).41

Many studies have indicated that the ECM has strong discriminative ability.12,51-53 The Elixhauser measure has demonstrated increased predictive ability over the original CCI. However, despite its usefulness, the ECM consists of a large number of variables and does not allow for the formation of one summary score.11,12

Weighted Elixhauser Comorbidity Measure

Attempts have been made to modify the original ECM to include a system of weights.54,55 Van Walraven et al55 developed and validated a weighted ECM among adult patients who were admitted to Ottawa Hospital between January 1996 and September 2007. Investigators determined the association of the Elixhauser comorbidities with in-hospital mortality. Twenty-one comorbidity groups had a statistically significant association with in-hospital mortality after adjusting for all other comorbidity categories and were therefore identified as independently associated with in-hospital death. A scoring system was formed by dividing each regression coefficient by the smallest regression coefficient in the risk model and rounding to the nearest integer.55,56 This method demonstrated the strength of each comorbidity’s association with the outcome. The weights were summed and yielded an overall comorbidity score, with a possible range of −19 to +89.55 The weighted ECM (c-statistic = 0.763, 95% CI: 0.759–0.766) had similar discriminative ability to that of the original (c-statistic = 0.760, 95% CI: 0.756–0.764) and increased discrimination in comparison to the CCI (c-statistic = 0.745, 95% CI: 0.742–0.749).55 While the weighted Elixhauser measure demonstrated good predictive ability, it should be noted that the method of weight formation for this model was similar to the controversial manner of weighting in the original Charlson Index mentioned previously.37,38 Van Walraven and colleagues also suggested that comorbidities associated with a decreased risk of in-hospital mortality (i.e. a negative score) may be the result of bias in coding and may not provide an accurate reflection of the condition itself.55 Here, authors point out that patients with severe disease are less likely to have minor conditions coded, while healthy patients are more likely to have these conditions coded.55

Few studies have evaluated this measure within the setting of arthroplasty. Goltz et al56 investigated the ability of the weighted Elixhauser measure to predict 90-day readmission following THA and TKA. Investigators identified 14 comorbidities associated with the outcome and calculated weights as described by van Walraven et al.55,56 Among a validation cohort consisting of 2,005 patients who underwent THA or TKA, the weighted ECM (AUC 0.656, 95% CI: 0.60–0.71) did not show significant loss in predictive ability compared to the unweighted model (AUC 0.665).56

While there is evidence that adapting the ECM to provide a single score may be beneficial, additional studies show there is currently no consensus on the method of calculating weights or on which of the original Elixhauser variables should be included for risk estimation.54-56 A study conducted by Gagne et al57 combined the Elixhauser measure with the Charlson Index by grouping
similar comorbidity variables between the two indices. This model encompassed 37 conditions and incorporated weights by dividing the regression coefficient by 0.3 and rounding to the nearest integer.\(^5^4,5^7\) When assessed for predictive ability of 30-day mortality, investigators reported increased discrimination of the combined index (c-statistic = 0.860, 95% CI: 0.854–0.866) in comparison with both the Charlson Index (c-statistic = 0.839, 95% CI: 0.836–0.849) and the van Walraven-weighted ECM (c-statistic = 0.836, 95% CI: 0.834–0.847).\(^5^7\) Still it is worth noting the weights for both the weighted ECM and the combined measure were initially developed to predict mortality. This may present limitations when predicting other postoperative outcomes.\(^5^4,5^6\)

**Modified Frailty Index**

Another common risk tool is the modified Frailty Index.\(^5^8\) Velanovich et al\(^5^8\) developed this index to predict 30-day morbidity and mortality across all surgical specialties. Investigators identified 11 variables which overlapped between the Canadian Study of Health and Aging Frailty Index (CSHA-FI) and the preoperative variables from the NSQIP (Table 4).\(^5^8\) The total number of items present for a given patient was divided by 11, which provided an index value ranging between 0 and 1.\(^5^8\) Investigators also stratified operations based on work relative value units (RVUs) to control for level of complexity. Using the mFI among 971,434 surgical inpatients, each unit increase in index value was associated with an increased risk of 30-day mortality and morbidity within all surgical specialties.\(^5^8\)

Runner et al\(^5^9\) examined the mFI for its ability to predict 30-day mortality, postoperative complications, readmission, and reoperation among 90,260 patients identified in the NSQIP database who underwent primary THA.\(^5^9\) Among patients who had 0 to 4 of the 11 possible variables, risk of 30-day mortality doubled with increasing index value (OR = 2.10, 95% CI: 1.73–2.55, \( p < 0.001\)).\(^5^9\) There was no association between index value and deep vein thrombosis (DVT) (OR = 1.05, 95% CI: 0.96–1.15, \( p = 0.255\)); however, increasing mFI was significantly associated with higher rates of any complication (OR = 1.22, 95% CI: 1.19–1.25, \( p < 0.001\)), surgical site infection (SSI) (OR = 1.24, 95% CI: 1.13–1.36, \( p < 0.001\)), wound dehiscence (OR = 1.43, 95% CI: 1.24–1.65, \( p < 0.001\)), myocardial infarction (MI) (OR = 2.15, 95% CI: 1.89–2.44, \( p < 0.001\)), pulmonary embolism (PE)/pneumonia (OR = 1.79, 95% CI: 1.58–2.02, \( p < 0.001\)), and acute renal failure (OR = 2.30, 95% CI: 1.78–2.98, \( p < 0.001\)).\(^5^9\) The modified Frailty Index also had statistically significant associations with both 30-day readmission and reoperation (OR = 8.71, 95% CI: 2.11–35.98, \( p = 0.003\) and OR = 3.32, 95% CI: 1.36–8.11, \( p = 0.009\), respectively).\(^5^9\)

Further work by Bellamy et al\(^6^0\) performed similar tests using the index among 51,582 patients identified in the NSQIP database who underwent primary THA. Increasing mFI was associated with increased risk of 30-day mortality (OR = 2.45, 95% CI: 2.08–2.88, \( p < 0.001\)), readmission (OR = 1.43, 95% CI: 1.23–1.65, \( p < 0.001\)), and reoperation (OR = 1.36, 95% CI: 1.27–1.47, \( p < 0.001\)).\(^5^9,6^0\) Higher index value was also associated with higher rates of the complications mentioned by Runner et al;\(^5^9\) however, unlike the TKA cohort, increasing index score was associated with a higher risk of DVT (OR = 1.25, 95% CI: 1.08–1.46, \( p = 0.0035\)).\(^5^9,6^0\) The mFI also demonstrated a stronger association with 30-day readmission (OR = 14.72, 95% CI: 6.95–31.18, \( p < 0.001\)) and reoperation (OR = 6.52, 95% CI: 2.48–17.13, \( p < 0.001\)) than the ASA-PS classification.\(^6^0\)

Contradicting these findings, a study by Ondeck et al\(^1^4\) showed the mFI demonstrated poorer performance than the ASA classification among THA patients. In this study, investigators evaluated the ability of the mFI to predict adverse events among 64,792 patients who underwent THA. Upon analysis, the modified Frailty Index had an AUC of 0.567 (95% CI: 0.561–0.573), while the ASA classification had an AUC of 0.584 (95% CI: 0.578–0.589).\(^1^4\)

**5-Factor modified Frailty Index**

By 2015, only five of the 11 variables used within the 11-Factor mFI (mFI-11) remained in the NSQIP data.\(^6^1,6^2\) Therefore, Subramaniam et al\(^6^1\) used the remaining factors (Table 4), forming the 5-Factor mFI (mFI-5), and compared its predictive ability for mortality, complications, and 30-day readmission with that of the mFI-11.\(^6^1\) Comparison of the two indices was conducted using 2012 NSQIP data and revealed similar c-statistics for mortality (c-statistic = 0.905 for both), complications (c-statistic = 0.788 for both), and readmission (c-statistic = 0.688 for mFI-5, c-statistic = 0.687 for mFI-11).\(^6^1\) Within orthopaedic surgery, both indices showed good to strong predictive ability for mortality (c-statistic = 0.908 for mFI-5, c-statistic = 0.909 for mFI-11), complications (c-statistic = 0.765 for mFI-5, c-statistic = 0.766 for mFI-11), and 30-day readmission (c-statistic = 0.707 for mFI-5, c-statistic = 0.706 for mFI-11).\(^6^1\)

In the setting of arthroplasty, Traven et al\(^6^2\) used the five-factor modified Frailty Index among 140,158 THA patients and 226,398 TKA patients within the NSQIP database between 2005 and 2016. Within the THA cohort, each unit increase in mFI-5 value was significantly associated with increased risk of 30-day mortality (OR = 1.491, 95% CI: 1.283–1.732, \( p < 0.001\)), readmission (OR = 1.285, 95% CI: 1.232–1.341, \( p < 0.001\)), any complication (OR = 1.254, 95% CI: 1.209–1.302, \( p < 0.001\)), and SSI (OR = 1.209, 95% CI: 1.118–1.308, \( p < 0.001\)).\(^6^2\) Among TKA
patients, every increasing unit of mFl-5 was associated with increased risk of 30-day mortality (OR = 1.569, 95% CI: 1.340–1.838, p < 0.001), readmission (OR = 1.249, 95% CI: 1.206–1.293, p < 0.001), any complication (OR = 1.175, 95% CI: 1.140–1.211, p < 0.001), and deep SSI (OR = 1.438, 95% CI: 1.233–1.677, p < 0.001).62 As seen with the modified CCI, changes in available NSQIP data have affected the utility of the modified Frailty Index. While the 5-Factor mFl has demonstrated comparable predictive ability to that of the original, the possibility of continued changes in available data should be considered.

RxRisk-V

Inconsistent availability of diagnostic data prompted Sloan et al63 to develop the RxRisk. This risk measure was initially adapted from the Chronic Disease Score with the intention of identifying comorbid conditions and predicting healthcare spending among the Veterans Health Administration (VHA) population.63 Since its creation, the RxRisk-V has become a commonly used pharmacy-based measure when attempting to understand the burden of disease.53–66 To form this tool, National Drug Codes (NDCs) were translated into drug names and routes of administration using the Multum Lexicon.63 This information was then mapped to VHA product names and drug classes. Investigators defined 45 RxRisk-V categories using information regarding the drugs and drug classes, with each category representing a single comorbidity.63 The use of a drug by a patient could therefore be deemed as the presence of the associated comorbid condition.

Subsequent studies have modified the original RxRisk-V to include a varying number of comorbidity categories.64,67–69 Pratt et al67 developed an updated model of the RxRisk-V by mapping the index to codes from the Anatomical Therapeutic Chemical (ATC) classification system. The adapted RxRisk-V included a total of 46 categories.67 Investigators examined an unweighted model, in which the score was calculated as the number of relevant comorbidity categories for a given patient.67 An additional model incorporated a weighting system based on the odds ratio of each comorbidity category determined using logistic regression.67 The predictive ability of the RxRisk-V models for one-year mortality was then assessed among 135,406 veterans within the Australian Government’s Department of Veteran’s Affairs (DVA) administrative claims database.67 Pratt and colleagues reported increased predictive ability of the weighted RxRisk-V model (c-statistic = 0.786, 95% CI: 0.782–0.789, p < 0.0001) over the unweighted index (c-statistic = 0.751, 95% CI: 0.747–0.754, p < 0.0001).67 Both indices were better predictors of one-year mortality than a base model including age and gender (c-statistic: 0.738, 95% CI: 0.734–0.742).67 When validated among a cohort of 303,135 patients, the weighted RxRisk-V model demonstrated strong predictive ability of one-year mortality (c-statistic = 0.833, 95% CI: 0.829–0.837, p < 0.0001).67

Inacio et al64 evaluated the RxRisk-V for its ability to predict 90-day and one-year mortality among 11,848 THA patients and 18,972 TKA patients who underwent a hip or knee arthroplasty procedure between 2001 and 2012 that was subsidized by the Australian Government Department of Veterans’ Affairs.64 Among the THA cohort, the RxRisk-V had a c-statistic of 0.72 for both outcomes.64 This was only slightly better than the base model which did not include comorbidity assessment and had a c-statistic of 0.69 for both outcomes.64 Among TKA patients, the RxRisk-V had a c-statistic of 0.75 and 0.73 for 90-day and one-year mortality, respectively, while the baseline model had a c-statistic of 0.69 and 0.70 for the respective outcomes.64

Another study by Inacio et al66 investigated the ability of the RxRisk-V to predict the risk of revision one year and five years following THA and TKA within the aforementioned cohorts. Among THA patients, the RxRisk-V had satisfactory predictive ability for both one-year revision (c-statistic = 0.61) and five-year revision (c-statistic = 0.60).66 The RxRisk-V also showed satisfactory predictive ability among the TKA cohort, with a c-statistic of 0.62 and 0.63 for revision after one year and five years, respectively.66

Inacio et al65 also evaluated the ability for the RxRisk-V to predict postoperative infections following total joint arthroplasty. Among the previously described cohorts of arthroplasty patients, this study showed the RxRisk-V did not have high predictive ability for estimating infection (c-statistic = 0.57).65

Overall, the RxRisk-V provides an alternative method of measuring comorbidities which may be beneficial in the absence of complete diagnostic information. However, within orthopaedic studies, this risk measure has not demonstrated high predictive ability among arthroplasty patients.64–66

Conclusion

The presence of comorbid disease can have a substantial impact on patient mortality, postoperative complications, use of hospital resources, and reimbursement. Several comorbidity measures currently exist to estimate the risk of various clinical outcomes in the face of these conditions. Inconsistent performance and sparse validation of comorbidity indices to predict revision, readmission, patient-reported outcomes (e.g. Oxford Hip and Knee Scores, EQ-5D index), and mortality in orthopaedic literature indicate a need for an improved method of predicting risks, especially within elective THA and TKA studies. Future research should explore the development of a standardized comorbidity measure that is tailored for use among the specific patient population in orthopaedics (e.g. arthroplasty).
ICMJE CONFLICT OF INTEREST STATEMENT
Dr. Piuzzi has disclosed the following conflicts of interest: institutional or research support from RegenLab and Zimmer; paid consultant for Regeneron and Stryker; editorial or governing board of the Journal of Hip Surgery and Journal of Knee Surgery; board or committee member of the American Association of Hip and Knee Surgeons, the International Society of Cell and Gene Therapy, and the Orthopaedic Research Society.

FUNDING STATEMENT
No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

SOCIAL MEDIA
@nspiuuzzi; @alisonklika; @CleClinicArthGp

OPEN ACCESS
© 2021 The author(s)
This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.

REFERENCES
1. Price AJ, Alvand A, Troelsen A, et al. Knee replacement. Lancet 2018;392:1672–1682.
2. Ferguson RJ, Palmer AJ, Taylor A, Porter ML, Malchau H, Glyn-Jones S. Hip replacement. Lancet 2018;392:1662–1671.
3. Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the US, 2014 to 2030. J Bone Joint Surg [Am] 2018;100-A:1455–1460.
4. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty. J Bone Joint Surg [Am] 2007;89-A:780–785.
5. Inacio MCS, Paxton EW, Graves SE, Nambha RS, Nemes S. Projected increase in total knee arthroplasty in the United States: an alternative-projection model. Osteoarthritis Cartilage 2017;25:1797–1803.
6. Bashinskyaya B, Zimmerman RM, Walcott BP, Antoci V. Arthroplasty utilization in the United States is predicted by age-specific population groups. ISRN Orthop 2012;2012:7–8.
7. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009;7:357–363.
8. Castano-Betancourt MC, Fruschein Annichino R, de Azevedo e Souza Munhoz M, Gomes Machado E, Lipay MV, Marchi E. Identification of high-risk groups for complication after arthroplasty: predictive value of patient related risk factors. J Orthop Surg Res 2018;13:328.
9. Warren JA, George J, Anis HK, et al. Effects of estimated glomerular filtration rate on 30-day mortality and postoperative complications after total hip arthroplasty: a risk stratification instrument. J Arthroplasty 2020;35:786–793.
10. Oh C, Gold H, Slover J. Diagnosis of depression and other patient factors impacts length of stay after total knee arthroplasty. Arthroplast Today 2020;6:77–80.
11. Charlson ME, Pompei P, Ales KL, MacKenzie R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
12. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27.
13. Schneeeweiss S, Madure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000;29:891–898.
14. O’Neeck NT, Bohl DD, Boonratwat P, et al. Predicting adverse outcomes after total hip arthroplasty: a comparison of demographics, the American Society of Anesthesiologists class, the Modified Charlson Comorbidity Index, and the Modified Frailty Index. J Am Acad Orthop Surg 2018;26:735–743.
15. Saklad M. Grading of patients for surgical procedures. Anesthesiology 1947;2:281–284.
16. Daabiss M. American Society of Anaesthesiologists physical status classification. Indian J Anaesth 2011;55:111–115.
17. Fitz-Henry J. The ASA classification and peri-operative risk. Ann R Coll Surg Engl 2011;93:185–187.
18. Keats AS. The ASA classification of physical status: a recapitulation. Anesthesiology 1978;49:233–236.
19. Dripps RD, Lamont A, Eckenhoff JE. The role of anesthesia in surgical mortality. JAMA 1960;178:261–266.
20. Lübbecke A, Siljan AJ, Barea C, Prieto-Alhambra D, Carr AJ. Mapping existing hip and knee replacement registries in Europe. Health Policy 2018;122:548–557.
21. Joshi Y, Ali M, Pradhan N, Wainwright O. Correlation between ASA grade, BMI and length of stay of patients undergoing primary hip and knee arthroplasty. Does ‘cherry picking’ by the ITC affect NHS hospitals? J Bone Joint Surg [Br] 2012;94-B.
22. Hooper GJ, Rothwell AG, Hooper NM, Frampton C. The relationship between the American Society of Anesthesiologists physical rating and outcome following total hip and knee arthroplasty: an analysis of the New Zealand Joint Registry. J Bone Joint Surg [Am] 2012;94-A:1065–1070.
23. Ferguson RJ, Siljan AJ, Combescure C, et al. ASA class is associated with early revision and reoperation after total hip arthroplasty: an analysis of the Geneva and Swedish Hip Arthroplasty Registries. Acta Orthop 2019;90:324–330.
24. Teni FS, Burström K, Berg J, Leidl R, Rolfsen O. Predictive ability of the American Society of Anaesthesiologists physical status classification system on health-related quality of life of patients after total hip replacement: comparisons across eight EQ-5D-3L value sets. BMC Musculoskelet Disord 2020;21:441.
25. Siljan AJ, Combescure C, Ferguson RJ, et al. International variation in distribution of ASA class in patients undergoing total hip arthroplasty and its influence on mortality: data from an international consortium of arthroplasty registries. Acta Orthop 2021;92:304–310.
26. Bjorgul K, Novicoff WM, Saleh KJ. Evaluating comorbidities in total hip and knee arthroplasty: available instruments. J Orthop Traumatol 2010;11:203–209.
27. Abouleish A, Leib ML, Cohen N. ASA provides examples to each ASA physical status class. ASA Mont 2015;79:38–39.
28. Hurwitz EE, Simon M, Vinta SR, et al. Adding examples to the ASA physical status classification improves correct assignment to patients. Anesthesiology 2017;126:614–622.
29. Moltó A, Dougados M. Comorbidity indices. Clin Exp Rheumatol 2014;32:5–131–5–134.
30. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD–9–CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075–1079.
31. Deyo RA, Cherkin DC,iol MA. Adapting a clinical comorbidity index for use with ICD–9–CM administrative databases. J Clin Epidemiol 1992;45:613–619.
32. Quan H, Sundararajan V, Halfaon P, et al. Coding algorithms for defining comorbidities in ICD–9–CM and ICD–10 administrative data. Med Care 2005;43:737–746.
33. Roos LL, Sharp SM, Cohen MM, Wajda A. Risk adjustment in claims-based research: the search for efficient approaches. J Clin Epidemiol 1989;42:1193–1206.
34. Medical C. A new method of classifying prognostic in longitudinal studies: development. J Chronic Dis 1987;40:373–383.
35. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676–682.
36. Brusselaers N, Lagergren J. The Charlson comorbidity index in registry-based research. Methods Inf Med 2017;56:401–406.
37. Mehta HB, Mehta V, Girman CJ, Adhikari D, Johnson ML. Regression coefficient-based scoring system should be used to assign weights to the risk index. J Clin Epidemiol 2016;79:22–28.
38. Knottnerus JA, Tugwell P, Wells G. Editorial comment: ratios should be multiplied, not added. J Clin Epidemiol 2016;79:39.
39. Voskuil T, Hageman M, Ring D. Higher Charlson Comorbidity Index scores are associated with readmission after orthopaedic surgery. Clin Orth Relat Res 2014;472:1658–1664.
40. Melfi C, Holleman E, Arthur D, Katz B. Selecting a patient characteristics index for the prediction of medical outcomes using administrative claims data. J Clin Epidemiol 1995;48:917–926.
41. Greene ME, Rolfsen O, Gordon M, Garlelick G, Nemes S. Standard comorbidity measures do not predict patient-reported outcomes 1 year after total hip arthroplasty. Clin Orth Relat Res 2015;473:3370–3379.
42. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245–1251.
43. Jiang L, Chou ACC, Nadkarni N, et al. Charlson Comorbidity Index predicts 5-year survivorship of surgically treated hip fracture patients. Geriatr Orth Surg Rehabil 2018;9:1–7.
44. Lakomkin N, Goz V, Lajam CM, Iorio R, Bosco JA III. Higher Modified Charlson Index scores are associated with increased incidence of complications, transfusion events, and length of stay following revision hip arthroplasty. J Arthroplasty 2017;32:1121–1124.
45. Mesko NW, Bachmann KR, Kovacevic D, LoGrasso ME, O’Rourke C, Froimson MI. Thirty-day readmission following total hip and knee arthroplasty: a preliminary single institution predictive model. J Arthroplasty 2014;29:1532–1538.
46. Onderk NT, Bohl DD, Bovonratwet P, et al. Discriminative ability of commonly used indices to predict adverse outcomes after posterior lumbar fusion: a comparison of demographics, ASA, the modified Charlson Comorbidity Index, and the modified Frailty Index. Spine J 2018;18:44–52.
47. Shultz BN, Ottesen TD, Onderk NT, et al. Systematic changes in the national surgical quality improvement program database over the years can affect comorbidity indices such as the Modified Frailty Index and Modified Charlson Comorbidity Index for lumbar fusion studies. Spine 2018;43:798–804.
48. Fortin Y, Crispo JAG, Cohen D, McNair DS, Mattison DR, Krewski D. External validation and comparison of two variants of the Elixhauser comorbidity measures for all-cause mortality. PLoS One 2017;12:e0174379.
49. Bälow E. coder: an R package for code-based item classification and categorization. J Open Source Softw 2020;5:2916.
50. Onderk NT, Bohl DD, Bovonratwet P, McLynn RP, Cui JJ, Grauer JN. Discriminative ability of Elixhauser’s Comorbidity Measure is superior to other comorbidity scores for inpatient adverse outcomes after total hip arthroplasty. J Arthroplasty 2018;33:259–257.
51. Kim D, Jo H, Lee Y, Kim KO. Elixhauser comorbidity measures-based risk factors associated with 30-day mortality in elderly population after femur fracture surgery: a propensity score-matched retrospective case–control study. Acute Crit Care 2020;35:10–15.
52. Menendez ME, Ring D. A comparison of the Charlson and Elixhauser comorbidity measures to predict inpatient mortality after proximal humerus fracture. J Orthop Trauma 2015;29:488–493.
53. Menendez ME, Neuhaus V, van Dijk CN, Ring D. The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orth Relat Res 2014;472:2788–2788.
54. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 2003;38:1171–1120.
55. van Walraven C, Austin PC, Jennings A, Quan H, Forster A. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009;47:626–633.
56. Goltz DE, Ryan SP, Howell CB, Attarian D, Bolognesi MP, Seyler TM. A weighted index of Elixhauser comorbidities for predicting 90-day readmission after total joint arthroplasty. J Arthroplasty 2019;34:857–864.
57. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol 2011;64:749–759.
58. Velanovich V, Antoine H, Swartz A, Peters D, Rubinfeld I. Accumulating deficits model of frailty and postoperative mortality and morbidity: its application to a national database. J Surg Res 2013;183:104–110.
59. Runner RP, Bellamy JL, Vu CCL, Erens GA, Schenker ML, Guild GN III. Modified frailty index is an effective risk assessment tool in primary total knee arthroplasty. J Arthroplasty 2017;32:S177–S182.
60. Bellamy JL, Runner RP, Vu CCL, Schenker ML, Bradbury TL, Roberson JR. Modified Frailty Index is an effective risk assessment tool in primary total knee arthroplasty. J Arthroplasty 2017;32:2963–2968.
61. Subramaniam S, Aalberg JJ, Soriano RP, Divino CM. New 5-Factor Modified Frailty Index using American College of Surgeons NSQIP data. J Am Coll Surg 2018;226:173–181.e8.
62. Traven SA, Reeves RA, Sekar MG, Slone HS, Walton ZJ. New 5-Factor Modified Frailty Index predicts morbidity and mortality in primary hip and knee arthroplasty. *J Arthroplasty* 2019;34:140–144.

63. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. *Med Care* 2003;41:761–774.

64. Inacio MCS, Pratt NL, Roughhead EE, Graves SE. Evaluation of three co-morbidity measures to predict mortality in patients undergoing total joint arthroplasty. *Osteoarthritis Cartilage* 2016;24:1718–1726.

65. Inacio MCS, Pratt NL, Roughhead EE, Graves SE. Predicting infections after total joint arthroplasty using a prescription based comorbidity measure. *J Arthroplasty* 2015;30:1692–1698.

66. Inacio MCS, Pratt NL, Roughhead EE, Graves SE. Using medications for prediction of revision after total joint arthroplasty. *J Arthroplasty* 2015;30:2061–2070.

67. Pratt NL, Kerr M, Barratt JD, et al. The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System. *BMJ Open* 2018;8:e021122.

68. Walsh CA, Bennett KE, Wallace E, Cahir C. Identifying adherence patterns across multiple medications and their association with health outcomes in older community-dwelling adults with multimorbidity. *Value Health* 2020;23:1063–1071.

69. Johnson ML, El-Serag HB, Tran TT, Hartman C, Richardson P, Abraham NS. Adapting the Rx-Risk-V for mortality prediction in outpatient populations. *Med Care* 2006;44:793–797.